公开(公告)号：US09827331B2

公开(公告)日：2017-11-28

申请号：US14866493

申请日：2015-09-25

Applicant: CLSN Laboratories, Inc.

Inventor： Majed Matar ,  Jason Fewell ,  Danny H. Lewis ,  Khursheed Anwer

IPC: A61K48/00 ,  A61K38/20 ,  A61K47/48 ,  A61K9/19 ,  C12N15/113 ,  C12N5/00 ,  A61K9/00 ,  A61K9/127 ,  A61K31/70 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  C12N15/11 ,  C12N15/88 ,  A61K47/60 ,  A61K47/54 ,  A61K47/59 ,  A61K47/64 ,  A61K38/00

CPC classification number: A61K48/0041 ,  A61K9/0019 ,  A61K9/1272 ,  A61K9/19 ,  A61K31/70 ,  A61K38/00 ,  A61K38/208 ,  A61K47/26 ,  A61K47/36 ,  A61K47/38 ,  A61K47/554 ,  A61K47/59 ,  A61K47/60 ,  A61K47/6455 ,  A61K48/0075 ,  C12N5/00 ,  C12N15/111 ,  C12N15/113 ,  C12N15/88 ,  C12N2310/14 ,  C12N2320/32 ,  C12N2510/00

Abstract: Compositions, methods, and applications that increase the efficiency of nucleic acid transfection are provided. In one aspect, a pharmaceutical composition may include at least about 0.5 mg/ml concentration of a nucleic acid condensed with a cationic lipopolymer suspended in an isotonic solution, where the cationic lipopolymer includes a cationic polymer backbone having cholesterol and polyethylene glycol covalently attached thereto, and wherein the molar ratio of cholesterol to cationic polymer backbone is within a range of from about 0.1 to about 10, and the molar ratio of polyethylene glycol to cationic polymer backbone is within a range of from about 0.1 to about 10. The composition further may include a filler excipient.

公开(公告)号：US09808533B2

公开(公告)日：2017-11-07

申请号：US15144440

申请日：2016-05-02

Applicant: Nektar Therapeutics

Inventor： Xuan Zhao ,  Michael David Bentley ,  Zhongxu Ren ,  Tacey X. Viegas

IPC: A61K9/00 ,  A61K47/48 ,  A61K31/4709

CPC classification number: A61K47/64 ,  A61K31/4709 ,  A61K31/4745 ,  A61K47/48192 ,  A61K47/48207 ,  A61K47/48215 ,  A61K47/4823 ,  A61K47/59 ,  A61K47/595 ,  A61K47/60 ,  A61K47/61 ,  C08G65/3314 ,  C08G65/3324 ,  C08G65/33317 ,  C08G65/3348 ,  C08L2203/02

Abstract: Provided herein are water-soluble prodrugs, compositions comprising such prodrugs, and related methods of making and administering the same. The prodrugs of the invention comprise a water-soluble polymer having three or more arms, at least three of which are typically covalently attached to an active agent, e.g., a small molecule. The conjugates of the invention provide an optimal balance of polymer size and structure for achieving improved drug loading, since the conjugates of the invention possess three or more active agents releasably attached to a multi-armed water-soluble polymer. The prodrugs of the invention are therapeutically effective, and exhibit improved properties in-vivo when compared to unmodified parent drug.

公开(公告)号：US09789194B2

公开(公告)日：2017-10-17

申请号：US15056386

申请日：2016-02-29

Applicant: Rutgers, The State University of New Jersey ,  US Army, Secretary of the Army

Inventor： David Devore ,  Charles Roth

IPC: C12N15/11 ,  C08F293/00 ,  A61K9/127 ,  A61K47/32 ,  C12N15/113 ,  A61K47/48 ,  A61K31/711 ,  A61K31/713 ,  A61K31/70 ,  C08G81/02 ,  C08F265/02

CPC classification number: A61K47/59 ,  A61K9/1272 ,  A61K31/70 ,  A61K31/711 ,  A61K31/713 ,  A61K47/6911 ,  C08F265/02 ,  C08G81/025

Abstract: Graft copolymer polyelectrolyte complexes are disclosed for the efficient delivery of anionic, cationic or polyelectrolyte therapeutic agents into biological cells, and for maintaining the biological activity of these molecules while in serum and other aqueous environments are provided. Such complexes comprise (1) an anionic graft copolymer containing an anionic polymer backbone, with pendent carboxylic acid groups and pendant chains containing amphipathic or hydrophilic polymers covalently bonded to a portion of the pendant carboxylic acid groups, (2) one or more anionic, cationic or polyelectrolyte therapeutic agents, and (3) optionally a liposome optionally containing an additional therapeutic agent. Also disclosed are functional nanoparticles containing the complexes.

公开(公告)号：US20170266268A1

公开(公告)日：2017-09-21

申请号：US15437405

申请日：2017-02-20

Applicant: CureVac AG

Inventor： Karl-Josef KALLEN ,  Thomas KRAMPS ,  Margit SCHNEE ,  Benjamin PETSCH ,  Lothar STITZ

IPC: A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K45/06

CPC classification number: A61K39/155 ,  A61K39/00 ,  A61K39/12 ,  A61K39/145 ,  A61K45/06 ,  A61K47/59 ,  A61K47/6455 ,  A61K47/6921 ,  A61K2039/53 ,  A61K2039/54 ,  A61K2039/55 ,  A61K2039/55583 ,  A61K2039/572 ,  A61K2039/575 ,  A61K2039/6031 ,  A61K2039/622 ,  A61P31/16 ,  C12N2760/16134 ,  C12N2760/18534 ,  C12N2760/18571 ,  Y02A50/412 ,  Y02A50/486 ,  Y02A50/487

Abstract: The present invention relates to vaccines comprising at least one mRNA encoding at least one antigen for use in the treatment of a disease in newborns and/or infants, preferably exhibiting an age of not more than 2 years, preferably of not more than 1 year, more preferably of not more than 9 months or even 6 months, wherein the treatment comprises vaccination of the newborn or infant and eliciting an immune response in said newborn or infant. The present invention is furthermore directed to kits and kits of parts comprising such a vaccine and/or its components and to methods applying such a vaccine or kit.

公开(公告)号：US09765335B2

公开(公告)日：2017-09-19

申请号：US14364611

申请日：2012-12-11

Applicant: Catholic University of Korea Industry-Academy Cooperation Foundation

Inventor： Kun Na ,  Sin Jung Park

IPC: C12N15/113 ,  C12N13/00 ,  A61K41/00 ,  A61K47/48 ,  C12N15/87 ,  A61K47/59 ,  A61K47/64 ,  A61K47/69 ,  A61K48/00

CPC classification number: C12N15/1136 ,  A61K41/0057 ,  A61K41/0071 ,  A61K47/59 ,  A61K47/595 ,  A61K47/645 ,  A61K47/6935 ,  A61K47/6939 ,  A61K48/00 ,  A61K48/0041 ,  C12N13/00 ,  C12N15/113 ,  C12N15/87 ,  C12N2310/14 ,  C12N2320/32 ,  Y10T428/2982

Abstract: A gene nanocomposite and a cellular internalization method of a gene using the same are provided. More specifically provided is a gene nanocomposite including: a photosensitizer-conjugated polymer; and one or more materials selected from a gene and a gene/cationic polymer composite, and a cellular internalization method of a gene using the same to improve gene delivery efficiency into a mammal-derived cell and gene expression.

公开(公告)号：US20170252460A1

公开(公告)日：2017-09-07

申请号：US15598505

申请日：2017-05-18

Applicant: Nicolai Bovin ,  Stephen HENRY ,  Iain HOSIE ,  Stephen PARKER

Inventor： Nicolai Bovin ,  Stephen HENRY ,  Iain HOSIE ,  Stephen PARKER

IPC: A61K31/7028 ,  A61L27/18 ,  D01F1/10 ,  C07F9/655 ,  C07F9/6558 ,  C07F9/6561 ,  A61L27/16 ,  A61K49/00 ,  A61L27/20 ,  A61L27/54 ,  A61L15/26 ,  A61L15/28 ,  A61L15/44 ,  D01D5/00 ,  C08L1/12 ,  C08L29/14 ,  C08G69/42

CPC classification number: A61K47/6953 ,  A61K31/7028 ,  A61K47/543 ,  A61K47/544 ,  A61K47/551 ,  A61K47/59 ,  A61K47/595 ,  A61K47/61 ,  A61K47/6435 ,  A61K49/0043 ,  A61K49/0054 ,  A61K49/0093 ,  A61L15/26 ,  A61L15/28 ,  A61L15/44 ,  A61L27/16 ,  A61L27/18 ,  A61L27/20 ,  A61L27/54 ,  A61L2300/22 ,  A61L2300/60 ,  A61L2400/14 ,  A61L2430/00 ,  C07F9/65522 ,  C07F9/65586 ,  C07F9/6561 ,  D01D5/003 ,  D01D5/0069 ,  D01F1/10 ,  C08L1/12 ,  C08L29/14

Abstract: Methods for functionalizing the surface of nanofiber substrates, including electrospun fibres and non-woven or woven mats of fibres are described. Functionalised nanofiber substrates presenting biologically active moieties such as biotin and saccharides are described.

公开(公告)号：US20170252455A1

公开(公告)日：2017-09-07

申请号：US15380734

申请日：2016-12-15

Applicant: ethris GmbH

Inventor： Carsten Rudolph ,  Johannes-Peter Geiger

IPC: A61K48/00 ,  C12N15/88 ,  A61K9/00 ,  C07H21/04 ,  A61K31/557 ,  C07K19/00 ,  A61K47/48

CPC classification number: A61K47/48038 ,  A61K9/007 ,  A61K47/542 ,  A61K47/549 ,  A61K47/59 ,  A61K47/643 ,  A61K48/0033 ,  A61K48/0041 ,  C12N15/88

Abstract: Described is a conjugate of agent complex and at least one target-finding ligand, where the agent complex comprises an agent encapsulated by an encapsulation material and where the target-finding ligand is a prostacyclin analog, and the use of the conjugate.

公开(公告)号：US09738684B2

公开(公告)日：2017-08-22

申请号：US14754002

申请日：2015-06-29

Applicant: COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH

Inventor： Pasha Santosh ,  Dewangan Rikeshwer Prasad ,  Joshi Seema

IPC: C07K5/078 ,  A61K47/48 ,  C07D209/04

CPC classification number: C07K5/06156 ,  A61K47/59 ,  C07D209/04 ,  C07D209/16

Abstract: N-terminally modified linear and branched polyamine conjugated peptidomimetics as antimicrobials agents. The invention relates to therapeutically viable antibacterial compositions based on ultra short mimetic of host defense cationic peptides (HDCPs). The invention relates to template based N-terminal modified di-peptidomimetics with or without modifications in polyamine backbone as new antibacterial agents. Most active peptidomimetics were bactericidal and caused a rapid decrease in viability of broad range of Gram-positive and Gram-negative bacterial strains in low micromolar concentration range including activity against clinically relevant pathogen methicillin resistant S. aureus (MRSA) andmethicillin resistant S. epidermidis(MRSE). Further the peptidomimetics were effective against MRSA biofilms (formation inhibition/killing of preformed biofilms) in vitro and were non toxic to human red blood cells and peripheral blood mononuclear cells. The molecules described in present invention do not develop resistance against MRSA under in vitro conditions and hence may be used as topical agents or in similar applications.

公开(公告)号：US20170232038A1

公开(公告)日：2017-08-17

申请号：US15504616

申请日：2015-08-20

Applicant: National University of Ireland, Galway

Inventor： Vincent O'FLAHERTY ,  Paul MC CAY

IPC: A61K33/18 ,  A61K9/06 ,  A23C7/02 ,  A61K8/20 ,  A61Q11/00 ,  A23C3/08 ,  A61K9/00 ,  A01N59/12

CPC classification number: A61K33/18 ,  A01N25/22 ,  A01N59/12 ,  A23C3/08 ,  A23C7/02 ,  A61K8/20 ,  A61K9/0014 ,  A61K9/0041 ,  A61K9/0043 ,  A61K9/0078 ,  A61K9/06 ,  A61K9/7007 ,  A61K47/02 ,  A61K47/20 ,  A61K47/59 ,  A61Q11/00 ,  A01N59/00 ,  A01N59/24

Abstract: The invention is concerned with a pharmaceutical and industrial iodophor preparation, its synthesis and potential applications. The compound has predictable antimicrobial activities. Furthermore, this iodophor is much more stable in the presence of organic material than traditional iodophors. The compositions release free iodine when in solution, which provides the antimicrobial activity.

公开(公告)号：US20170210853A1

公开(公告)日：2017-07-27

申请号：US15326866

申请日：2015-07-10

Applicant: Universiteit Gent

Inventor： Richard HOOGENBOOM ,  Bryn MONNERY

IPC: C08G73/02 ,  A61K47/34

CPC classification number: C08G73/0233 ,  A61K47/34 ,  A61K47/59 ,  C08L79/02

Abstract: A method for production of a uniform polymer of high molar mass is provides, the method comprising: (a) polymerizing cyclic imino ether monomer in a first reaction mixture by cationic ring opening polymerization to produce a polymerized first reaction mixture containing (i) polymerized material and (ii) solvent and/or unreacted cyclic imino ether monomer; (b) separating solvent and/or unreacted cyclic imino ether monomer from polymerized material contained in the polymerized first reaction mixture; (c) copolyerizing by cationic ring opening polymerization a second liquid reaction mixture containing cyclic imino ether monomer and solvent by combining the separated unreacted cyclic imino ether monomer and/or the separated solvent with other components. Also disclosed are polyoxazoline polymers comprising at least 50 wt. % of repeating units derived from a 2-substituted 2-oxazoline monomer selected from 2-methyl-2-oxazoline, 2-ethyl-2-oxazoline, 2-n-propyl-2-oxazoline, 2-i-propyl-2-oxazoline and combinations thereof, said polymer having a DP of at least 250 and a very low dispersity.